Atherosclerosis and Hyperlipidemia Research

Atherosclerosis is a disorder of the arteries characterized by the formation of hard structures called atherosclerotic plaques. It is a prevalent disorder, accounting for one third of all deaths in North America.

Atherosclerosis and Hyperlipidemia Research Products Targets

Products for Atherosclerosis and Hyperlipidemia Research - Page 7

Cat.No. Product Name Information/Activity
BCC6365 iMDK 881970-80-5
BCC6023 4-IPP 4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF).
BCC5427 ISO-1 ISO-1 is a macrophage migration inhibitory factor (MIF) antagonist with an IC50 of 7 μM.
BCC7960 (D)-(+)-Neopterin D-(+)-Neopterin, a catabolic product of guanosine triphosphate (GTM), serves as a marker of cellular immune system activation.
BCC5086 Pirfenidone Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities.
BCC7236 SKF 86002 dihydrochloride 116339-68-5
BCC4961 Suplatast Tosylate Suplatast Tosilate (IPD 1151T) is a Th2 cytokine inhibitor that attenuates IL-2, IL-5 and IL-13 production and has no effect on IFN-γ production.
BCC2248 Thalidomide Thalidomide is initially promoted as a sedative, inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ∼250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties.
BCC2368 Sivelestat sodium salt Sivelestat sodium(ONO5046; LY544349; EI546) is a competitive inhibitor of human neutrophil elastase(IC50 = 44 nM; Ki=200 nM); also inhibited leukocyte elastase obtained from rabbit, rat, hamster and mouse.
BCC2319 Atorvastatin Calcium Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.